TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26250966

Group type: EXPERIMENTAL
Intervention: Nutritional Risk Index (NRI)
Number of subjects: 160

Group type: COMPARATOR
Intervention: ESCAPE mortality model
Number of subjects: 160
Study: 23915885

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) training
Number of subjects: 6771

Group type: EXPERIMENTAL
Intervention: Enhanced communication training
Number of subjects: 6771

Group type: EXPERIMENTAL
Intervention: Combined intervention (CRP and enhanced communication)
Number of subjects: 6771

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6771
Study: 21934290

Group type: EXPERIMENTAL
Intervention: Midazolam + alfentanil
Number of subjects: 115

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 115
Study: 18069027

Group type: EXPERIMENTAL
Intervention: Active TENS with high-intensity stimulation at segmental and extrasegmental sites
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 208
Study: 17070355

Group type: EXPERIMENTAL
Intervention: ProstaLund Feedback Treatment (PLFT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Surgery (TURP/prostate enucleation)
Number of subjects: 120
Study: 14763350

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 8
Study: 10883872

Group type: EXPERIMENTAL
Intervention: CHX mouthwash
Number of subjects: 40

Group type: COMPARATOR
Intervention: CHX spray
Number of subjects: 40
Study: 8926511

Group type: EXPERIMENTAL
Intervention: Experimental clinical teaching method using computer-assisted instruction (CAI) and a collaboration model during initial clinical experiences.
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 83
Study: 1443446

Group type: EXPERIMENTAL
Intervention: Formalinized depot grass allergoid (cumulative pre-seasonal dosage of 46,050 PNU)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Formalinized depot grass allergoid
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 6534451

Group type: EXPERIMENTAL
Intervention: Excretory cystography
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Excretory cystography for papillary tumours >= 0.5 cm
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Excretory cystography for tumours < 0.5 cm
Number of subjects: 100
Study: 29925930

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of rituximab with therapy targeting CD4+ T cells
Number of subjects: 0
Study: 27890801

Group type: EXPERIMENTAL
Intervention: EUS-guided paclitaxel injection (PTX) plus standard of care (SOC)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 137
Study: 25720672

Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 capsules once weekly for 8 weeks
Number of subjects: 112

Group type: COMPARATOR
Intervention: Starch capsules (placebo) once weekly for 8 weeks
Number of subjects: 112
Study: 23490393

Group type: EXPERIMENTAL
Intervention: Narlaprevir followed by PEG‐IFN/RBV
Number of subjects: 40
Study: 21819556

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 17.5 mg weekly
Number of subjects: 31

Group type: COMPARATOR
Intervention: Azathioprine (AZA) 2.5 mg/kg daily
Number of subjects: 31
Study: 19183127

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16460314

Group type: EXPERIMENTAL
Intervention: zeaxanthin (OPTISHARP) and/or lutein supplementation
Number of subjects: 24
Study: 14722336

Group type: EXPERIMENTAL
Intervention: active multicomponent counseling and support intervention
Number of subjects: 406

Group type: COMPARATOR
Intervention: usual care condition
Number of subjects: 406
Study: 11464310

Group type: EXPERIMENTAL
Intervention: Indomethacin 75 mg daily for 3 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 9876078

Group type: EXPERIMENTAL
Intervention: Submucosal sclerotherapy (1 or 2 sessions)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Transanal excision of the prolapsing mucosa
Number of subjects: 162
Study: 7864609

Group type: EXPERIMENTAL
Intervention: Children's behavioral neophobia levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children's and parents' behavioral and trait neophobia scores
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parents' neophobia with respect to foods of animal origin
Number of subjects: 0
Study: 2563616

Group type: EXPERIMENTAL
Intervention: Grenz ray therapy (5 Gy applied on 10 occasions at intervals of 1 week)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Simulated therapy (control)
Number of subjects: 22
Study: 799988

Group type: EXPERIMENTAL
Intervention: Imipramine (Tofranil) added to standard analgesic anti-rheumatic therapy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Imipramine (Tofranil)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 30391714

Group type: EXPERIMENTAL
Intervention: Sweet snack consumed post-dinner (19:30)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sweet snack consumed mid-afternoon (15:30)
Number of subjects: 17
Study: 27932679

Group type: EXPERIMENTAL
Intervention: NSAIDs (ibuprofen 1,200 mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (Plc)
Number of subjects: 19
Study: 25646876

Group type: EXPERIMENTAL
Intervention: Text messaging (eGEMs) three times per week for 12 weeks
Number of subjects: 269

Group type: COMPARATOR
Intervention: Control group (no text messages)
Number of subjects: 269
Study: 24228747

Group type: EXPERIMENTAL
Intervention: SSPANLI intervention (pedometer-based physical activity promotion and nutrition education)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Usual non-surgical care (control group)
Number of subjects: 106
Study: 22124225

Group type: EXPERIMENTAL
Intervention: 1-millisecond brief pulse ECT
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 0.3-millisecond ultrabrief pulse ECT
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison of brief pulse ECT vs ultrabrief pulse ECT
Number of subjects: 22
Study: 19118724

Group type: EXPERIMENTAL
Intervention: cilostazol
Number of subjects: 80

Group type: COMPARATOR
Intervention: control
Number of subjects: 80
Study: 16729788

Group type: EXPERIMENTAL
Intervention: Montelukast (4 mg tablet)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 15589861

Group type: EXPERIMENTAL
Intervention: urinary FSH (u-FSH)
Number of subjects: 34

Group type: COMPARATOR
Intervention: recombinant FSH (r-FSH)
Number of subjects: 34
Study: 11356893

Group type: EXPERIMENTAL
Intervention: Electrical stimulation over muscles that plantarflex the ankle (1 msec pulses, 100 Hz)
Number of subjects: 5
Study: 9215520

Group type: EXPERIMENTAL
Intervention: Single-session ('skills' group - low-intensity) intervention
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Five-session ('practice' group - high intensity) intervention
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Both intervention groups
Number of subjects: 333
Study: 8025136

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery (CABG) using internal mammary artery as conduit for revascularization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 0
Study: 3111354

Group type: EXPERIMENTAL
Intervention: 200 mg enoxacin
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 400 mg enoxacin
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 155
Study: 28885287

Group type: EXPERIMENTAL
Intervention: Bracing (rigid thoracolumbosacral orthosis, worn 23 hours/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Exercise (Scientific Exercise Approach to Scoliosis)
Number of subjects: 53
Study: 28139405

Group type: EXPERIMENTAL
Intervention: Idelalisib (150 mg orally twice daily) in combination with bendamustine and rituximab
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo in combination with bendamustine and rituximab
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Idelalisib
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study: 25141012

Group type: EXPERIMENTAL
Intervention: Non-pharmacological sleep extension
Number of subjects: 125
Study: 24346676

Group type: EXPERIMENTAL
Intervention: Nutritional guidelines and educational program for school lunch cooks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 20
Study: 20507568

Group type: EXPERIMENTAL
Intervention: Interspinous implant surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bony decompression surgery
Number of subjects: 0
Study: 18790154

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transanal excision using endoscopic microsurgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Robotic‐assisted laparoscopic surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimally invasive treatment for rectal cancer
Number of subjects: 0
Study: 16263817

Group type: EXPERIMENTAL
Intervention: 4.4 mg testosterone gel
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 8.8 mg testosterone gel
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 13.2 mg testosterone gel
Number of subjects: 26

Group type: COMPARATOR
Intervention: 0 mg testosterone gel
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All doses of testosterone gel
Number of subjects: 26
Study: 12684146

Group type: EXPERIMENTAL
Intervention: NuvaRing with nonoxynol‐9 co-medication
Number of subjects: 12

Group type: COMPARATOR
Intervention: NuvaRing without nonoxynol‐9
Number of subjects: 12
Study: 11027905

Group type: EXPERIMENTAL
Intervention: Ketamine 0.25 mg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ketamine 0.50 mg/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 10
Study: 8816645

Group type: EXPERIMENTAL
Intervention: 3.2, 3.5, and 4.5-millimeter cortical-bone screws; 3.5-millimeter cancellous-bone screw; 3.5-millimeter self-tapping screw with bicortical purchase
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3.5-millimeter self-tapping screw with unicortical or bicortical purchase
Number of subjects: 12
Study: 8156509

Group type: EXPERIMENTAL
Intervention: Continuous hyperthermic peritoneal perfusion (CHPP) with 10 micrograms/ml mitomycin C
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no CHPP)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Continuous hyperthermic peritoneal perfusion (CHPP)
Number of subjects: 82
Study: 3168696

Group type: EXPERIMENTAL
Intervention: pH-sensitive enteric-coated pancreatic enzyme preparation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional enzyme preparations
Number of subjects: 8
Study: 31710134

Group type: EXPERIMENTAL
Intervention: Nursing case management (includes nursing consultations, telephone contact, home visits, health education, and appropriate referrals)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Nursing case management
Number of subjects: 94
Study: 30033855

Group type: EXPERIMENTAL
Intervention: Daily dysmenorrhea and nonmenstrual pelvic pain impact items
Number of subjects: 0
Study: 28138971

Group type: EXPERIMENTAL
Intervention: Oral cannabis administration (6.9% [50.4 mg] THC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (0.001% THC)
Number of subjects: 0
Study: 26261389

Group type: EXPERIMENTAL
Intervention: Pudendal nerve block (Group I, n=62)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Caudal block (Group II, n=61)
Number of subjects: 123
Study: 24059116

Group type: EXPERIMENTAL
Intervention: rTMS treatment for 2 weeks (15 days) combined with selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Antidepressant treatment (SSRI) only
Number of subjects: 159

Group type: COMPARATOR
Intervention: Normal control group (group C)
Number of subjects: 159
Study: 21868346

Group type: EXPERIMENTAL
Intervention: Trsatuzumab (Herceptin) combined with FOLFIRI regimen (irinotecan plus 5‐FU/LV)
Number of subjects: 34

Group type: COMPARATOR
Intervention: FOLFIRI regimen alone
Number of subjects: 34
Study: 18974308

Group type: EXPERIMENTAL
Intervention: Combination therapy (cognitive behavioral therapy + sertraline)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Sertraline (up to 200 mg per day)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: All therapies
Number of subjects: 488
Study: 16832415

Group type: EXPERIMENTAL
Intervention: Genetic nurse counsellor
Number of subjects: 586

Group type: COMPARATOR
Intervention: Clinical geneticist (current service)
Number of subjects: 586
Study: 12892241

Group type: EXPERIMENTAL
Intervention: Dynamic lumbar stabilization exercises
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Home exercise programme
Number of subjects: 42

Group type: COMPARATOR
Intervention: No exercises (Control group)
Number of subjects: 42
Study: 10852274

Group type: EXPERIMENTAL
Intervention: i.v. clodronate 300 mg daily for 10 consecutive days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 7486185

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 60
Study: 2307806

Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Lower concentrations of sucrose
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Higher concentrations of sucrose
Number of subjects: 27
Study: 6784264

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All active drugs (Propranolol, Atenolol, Metoprolol)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All drugs (including placebo)
Number of subjects: 8
Study: 31081475

Group type: EXPERIMENTAL
Intervention: Neuraxial analgesia
Number of subjects: 389

Group type: COMPARATOR
Intervention: No neuraxial analgesia (Control)
Number of subjects: 389
Study: 28471950

Group type: EXPERIMENTAL
Intervention: Modified MSLT performed in the unattended home
Number of subjects: 34

Group type: COMPARATOR
Intervention: Modified MSLT performed in the hospital
Number of subjects: 34
Study: 25547112

Group type: EXPERIMENTAL
Intervention: computer‐generated interactive visual feedback training
Number of subjects: 12

Group type: COMPARATOR
Intervention: mirror visual feedback training
Number of subjects: 12
Study: 23398944

Group type: EXPERIMENTAL
Intervention: 10 mg/d lutein
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 20 mg/d lutein
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 21290392

Group type: EXPERIMENTAL
Intervention: 940 nm laser treatment (GR1)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Topical PA agent indocyanine-green followed by 810 nm laser treatment (GR2)
Number of subjects: 23
Study: 19118130

Group type: EXPERIMENTAL
Intervention: Distributed Constraint-Induced Therapy (CIT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bilateral Arm Training (BAT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 60
Study: 17185355

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 15503853

Group type: EXPERIMENTAL
Intervention: Persica mouthwash
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 11471604

Group type: EXPERIMENTAL
Intervention: Small bowel enema (SBE)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Barium follow-through (FT)
Number of subjects: 244
Study: 9770738

Group type: EXPERIMENTAL
Intervention: Diltiazem (60-90 mg 4 times a day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nifedipine (20-30 mg 4 times a day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Diltiazem (single dose)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Nifedipine (single dose)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nifedipine (long-term treatment)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Diltiazem (long-term treatment)
Number of subjects: 17
Study: 7885111

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with autologous stem cell support
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard dose chemotherapy
Number of subjects: 33
Study: 2593192

Group type: EXPERIMENTAL
Intervention: Manual ventilation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Transport ventilator
Number of subjects: 28
Study: 1092033

Group type: EXPERIMENTAL
Intervention: Betahistine hydrochloride
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 30658935

Group type: EXPERIMENTAL
Intervention: PET-driven treatment (ABVD after positive PET2 or BEACOPPescalated after negative PET2)
Number of subjects: 823

Group type: COMPARATOR
Intervention: Standard treatment (BEACOPPescalated for all cycles)
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: PET-driven treatment (ABVD after positive PET2)
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: PET-driven treatment
Number of subjects: 823

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 823
Study: 24659024

Group type: EXPERIMENTAL
Intervention: Airex® pad training (intervention group)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (without the pad)
Number of subjects: 11
Study: 22584456

Group type: EXPERIMENTAL
Intervention: Adjunctive telephone coaching and electronic contact (ATC) with the Loozit group program (n=73)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Loozit group program alone (n=78)
Number of subjects: 151
Study: 21414746

Group type: EXPERIMENTAL
Intervention: All-polyethylene tibial component
Number of subjects: 47

Group type: COMPARATOR
Intervention: Metal-backed modular version of the implant
Number of subjects: 47
Study: 19001014

Group type: EXPERIMENTAL
Intervention: Behavioural intervention group (N = 249)
Number of subjects: 491

Group type: COMPARATOR
Intervention: Usual care group (N = 242)
Number of subjects: 491
Study: 16761192

Group type: EXPERIMENTAL
Intervention: Rilmenidine (0.5 mg)
Number of subjects: 32
Study: 14726225

Group type: EXPERIMENTAL
Intervention: Pilot trials with six subjects
Number of subjects: 6
Study: 11131210

Group type: EXPERIMENTAL
Intervention: Quantum HF-6700 oxygenator
Number of subjects: 20

Group type: COMPARATOR
Intervention: HF-5700 oxygenator
Number of subjects: 20
Study: 9339113

Group type: EXPERIMENTAL
Intervention: IVIG (500 mg/kg for >1500 g, 700 mg/kg for <1500 g) on days 1, 2, and 8
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no IVIG)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 80
Study: 8408940

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Inspiratory Resistance - Positive Expiratory Pressure (IR-PEP)
Number of subjects: 160
Study: 3158273

Group type: COMPARATOR
Intervention: Standard breakfast (B)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bioassay measurement
Number of subjects: 10
Study: 29661678

Group type: EXPERIMENTAL
Intervention: Propofol (0.5 mg kg‐1; group PP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Saline (group CP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Propofol infusion (1.3 mg kg‐1 minute‐1; group SI)
Number of subjects: 32
Study: 27621264

Group type: EXPERIMENTAL
Intervention: Preemptive local anesthesia combined with general anesthesia (Group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Preemptive local anesthesia combined with spinal anesthesia (Group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo with general anesthesia (Group C)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo with spinal anesthesia (Group D)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Preemptive local anesthesia (Groups A and B)
Number of subjects: 80
Study: 24309022

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (100 million CFU/day)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 21431100

Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 0
Study: 19020919

Group type: EXPERIMENTAL
Intervention: Antioxidants (600 mg vitamin E and 1,000 mg vitamin C daily)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Resistance exercise (3x/week)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 17234902

Group type: EXPERIMENTAL
Intervention: Elastase
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Neutrophil counts
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: IL-8
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Bacterial densities
Number of subjects: 269
Study: 15480278

Group type: EXPERIMENTAL
Intervention: Methotrexate-mifepristone (600 mg given orally)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Methotrexate-placebo
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Methotrexate-mifepristone (600 mg given orally) with progesterone level 10 ng/l
Number of subjects: 212

Group type: COMPARATOR
Intervention: Methotrexate-placebo with progesterone level 10 ng/l
Number of subjects: 212
Study: 11566521

Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1% eyedrops for 2 months after surgery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Flurbiprofen 0.03% eyedrops for 2 months after surgery
Number of subjects: 24
Study: 9636863

Group type: EXPERIMENTAL
Intervention: Combination therapy with fluconazole (200 mg once a day for 2 months) and flucytosine (150 mg/(kg.d) for the first 2 weeks)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Combination therapy with fluconazole and flucytosine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Fluconazole monotherapy (200 mg once a day for 2 months)
Number of subjects: 58